{"entity":{"type":"insider","cik":"0001250195","url":"/insider/0001250195","json_url":"/insider/0001250195.json","name":"ELMS STEVE","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":45,"n_filings":35,"first":"2010-03-12","last":"2026-03-09","span_basis":"filed_date"},"name_variants":[{"name":"ELMS STEVE","source":"filing","n_filings":35,"first_seen":"2010-03-12","last_seen":"2026-03-09"}],"transactions":[{"id":5796514,"accession":"0001140361-26-008363","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-008363","line_url":"/filing/0001140361-26-008363#line-2","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7000.0,"shares_display":"7,000","price_per_share":15.39,"price_display":"15.39","price_state":"stated","total_value":107730.0,"total_display":"107,730.00","total_whole":"107,730","shares_owned_after":2045730.0,"shares_owned_after_display":"2,045,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-09","scope":"insider"},{"id":5796512,"accession":"0001140361-26-008363","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-26-008363","line_url":"/filing/0001140361-26-008363#line-1","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7000.0,"shares_display":"7,000","price_per_share":15.67,"price_display":"15.67","price_state":"stated","total_value":109690.0,"total_display":"109,690.00","total_whole":"109,690","shares_owned_after":2038730.0,"shares_owned_after_display":"2,038,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-05","filed_date":"2026-03-09","scope":"insider"},{"id":5068623,"accession":"0001140361-25-022713","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001140361-25-022713","line_url":"/filing/0001140361-25-022713#line-13","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":194749.0,"shares_display":"194,749","price_per_share":20.24,"price_display":"20.24","price_state":"stated","total_value":3941719.76,"total_display":"3,941,719.76","total_whole":"3,941,720","shares_owned_after":87330.0,"shares_owned_after_display":"87,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-16","scope":"insider"},{"id":5068619,"accession":"0001140361-25-022713","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001140361-25-022713","line_url":"/filing/0001140361-25-022713#line-12","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":137931.0,"shares_display":"137,931","price_per_share":20.82,"price_display":"20.82","price_state":"stated","total_value":2871723.42,"total_display":"2,871,723.42","total_whole":"2,871,723","shares_owned_after":282079.0,"shares_owned_after_display":"282,079","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-16","scope":"insider"},{"id":5068584,"accession":"0001140361-25-022713","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-25-022713","line_url":"/filing/0001140361-25-022713#line-1","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":92941.0,"shares_display":"92,941","price_per_share":21.69,"price_display":"21.69","price_state":"stated","total_value":2015890.29,"total_display":"2,015,890.29","total_whole":"2,015,890","shares_owned_after":2031730.0,"shares_owned_after_display":"2,031,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-12","filed_date":"2025-06-16","scope":"insider"},{"id":2147525,"accession":"0001104659-24-131704","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-131704","line_url":"/filing/0001104659-24-131704#line-1","is_derivative":false,"issuer_cik":"0001094038","issuer_name":"Marker Therapeutics, Inc.","issuer_ticker":"MRKR","issuer_name_source":null,"issuer_url":"/issuer/0001094038","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11085.0,"shares_display":"11,085","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":35472.0,"total_display":"35,472.00","total_whole":"35,472","shares_owned_after":325370.0,"shares_owned_after_display":"325,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-26","scope":"insider"},{"id":2841763,"accession":"0001140361-24-014226","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-24-014226","line_url":"/filing/0001140361-24-014226#line-2","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":411829.0,"shares_display":"411,829","price_per_share":6.08,"price_display":"6.08","price_state":"stated","total_value":2503920.32,"total_display":"2,503,920.32","total_whole":"2,503,920","shares_owned_after":2115671.0,"shares_owned_after_display":"2,115,671","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-19","filed_date":"2024-03-19","scope":"insider"},{"id":2841758,"accession":"0001140361-24-014226","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-24-014226","line_url":"/filing/0001140361-24-014226#line-1","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":49887.0,"shares_display":"49,887","price_per_share":6.01,"price_display":"6.01","price_state":"stated","total_value":299820.87,"total_display":"299,820.87","total_whole":"299,821","shares_owned_after":2527500.0,"shares_owned_after_display":"2,527,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-18","filed_date":"2024-03-19","scope":"insider"},{"id":2546257,"accession":"0001140361-24-013634","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-24-013634","line_url":"/filing/0001140361-24-013634#line-3","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":183008.0,"shares_display":"183,008","price_per_share":6.01,"price_display":"6.01","price_state":"stated","total_value":1099878.08,"total_display":"1,099,878.08","total_whole":"1,099,878","shares_owned_after":2577387.0,"shares_owned_after_display":"2,577,387","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-15","filed_date":"2024-03-15","scope":"insider"},{"id":2546252,"accession":"0001140361-24-013634","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-24-013634","line_url":"/filing/0001140361-24-013634#line-2","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":448276.0,"shares_display":"448,276","price_per_share":6.05,"price_display":"6.05","price_state":"stated","total_value":2712069.8,"total_display":"2,712,069.80","total_whole":"2,712,070","shares_owned_after":2760395.0,"shares_owned_after_display":"2,760,395","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-14","filed_date":"2024-03-15","scope":"insider"},{"id":2546246,"accession":"0001140361-24-013634","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-24-013634","line_url":"/filing/0001140361-24-013634#line-1","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":407000.0,"shares_display":"407,000","price_per_share":6.21,"price_display":"6.21","price_state":"stated","total_value":2527470.0,"total_display":"2,527,470.00","total_whole":"2,527,470","shares_owned_after":3208671.0,"shares_owned_after_display":"3,208,671","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-15","scope":"insider"},{"id":5334754,"accession":"0001209191-21-044561","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-044561","line_url":"/filing/0001209191-21-044561#line-3","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Elevation Oncology, Inc.","issuer_ticker":"ELEV","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners IV, LP; Aisling Capital Partners IV LLC; Aisling Capital IV, LP; SCHIFF ANDREW N; ELMS STEVE","owner_display_name":"Aisling Capital Partners IV, LP","owner_url":null,"role":"Director, Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":187500.0,"shares_display":"187,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":2834910.0,"shares_owned_after_display":"2,834,910","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"},{"id":4528875,"accession":"0001209191-21-021769","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-021769","line_url":"/filing/0001209191-21-021769#line-1","is_derivative":false,"issuer_cik":"0001094038","issuer_name":"Marker Therapeutics, Inc.","issuer_ticker":"MRKR","issuer_name_source":null,"issuer_url":"/issuer/0001094038","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1142857.0,"shares_display":"1,142,857","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":1999999.75,"total_display":"1,999,999.75","total_whole":"2,000,000","shares_owned_after":3142857.0,"shares_owned_after_display":"3,142,857","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-16","filed_date":"2021-03-18","scope":"insider"},{"id":8143763,"accession":"0000899243-19-019602","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-019602","line_url":"/filing/0000899243-19-019602#line-1","is_derivative":false,"issuer_cik":"0001061027","issuer_name":"SUNESIS PHARMACEUTICALS INC","issuer_ticker":"SNSS","issuer_name_source":null,"issuer_url":"/issuer/0001061027","owner_cik":null,"owner_name":"Aisling Capital IV, LP; SCHIFF ANDREW N; Aisling Capital Partners IV, LP; ELMS STEVE; Aisling Capital Partners IV LLC","owner_display_name":"Aisling Capital IV, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":0.6,"price_display":"0.60","price_state":"stated","total_value":1500000.0,"total_display":"1,500,000.00","total_whole":"1,500,000","shares_owned_after":10100000.0,"shares_owned_after_display":"10,100,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-15","filed_date":"2019-07-15","scope":"insider"},{"id":6282955,"accession":"0000899243-18-019810","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-019810","line_url":"/filing/0000899243-18-019810#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; Aisling Capital Partners III LLC; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1400000.0,"shares_display":"1,400,000","price_per_share":179.43,"price_display":"179.43","price_state":"stated","total_value":251202000.0,"total_display":"251,202,000.00","total_whole":"251,202,000","shares_owned_after":2038920.0,"shares_owned_after_display":"2,038,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-10","filed_date":"2018-07-12","scope":"insider"},{"id":5159611,"accession":"0000950142-17-002235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-002235","line_url":"/filing/0000950142-17-002235#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; ELMS STEVE; Aisling Capital Partners III LLC; SCHIFF ANDREW N; Purcell Dennis J; Aisling Capital Partners III LP","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":80.5,"price_display":"80.50","price_state":"stated","total_value":20125000.0,"total_display":"20,125,000.00","total_whole":"20,125,000","shares_owned_after":3438920.0,"shares_owned_after_display":"3,438,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-19","filed_date":"2017-12-20","scope":"insider"},{"id":4735884,"accession":"0000950142-17-002107","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-002107","line_url":"/filing/0000950142-17-002107#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LP; ELMS STEVE","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":75.0,"price_display":"75.00","price_state":"stated","total_value":37500000.0,"total_display":"37,500,000.00","total_whole":"37,500,000","shares_owned_after":3688920.0,"shares_owned_after_display":"3,688,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-22","filed_date":"2017-11-27","scope":"insider"},{"id":5312278,"accession":"0000950142-17-000108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-17-000108","line_url":"/filing/0000950142-17-000108#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"ELMS STEVE; Aisling Capital Partners III LP; AISLING CAPITAL III LP; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LLC","owner_display_name":"ELMS STEVE","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":160000.0,"shares_display":"160,000","price_per_share":31.0,"price_display":"31.00","price_state":"stated","total_value":4960000.0,"total_display":"4,960,000.00","total_whole":"4,960,000","shares_owned_after":4188920.0,"shares_owned_after_display":"4,188,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-10","filed_date":"2017-01-12","scope":"insider"},{"id":2545318,"accession":"0000950142-16-004060","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-16-004060","line_url":"/filing/0000950142-16-004060#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":908565.0,"shares_owned_after_display":"908,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-06","scope":"insider"},{"id":3241927,"accession":"0000950142-16-003763","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-16-003763","line_url":"/filing/0000950142-16-003763#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; Aisling Capital Partners III LLC; Purcell Dennis J; ELMS STEVE; Aisling Capital Partners III LP; SCHIFF ANDREW N","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":232558.0,"shares_display":"232,558","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":4999997.0,"total_display":"4,999,997.00","total_whole":"4,999,997","shares_owned_after":4028920.0,"shares_owned_after_display":"4,028,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-17","filed_date":"2016-05-19","scope":"insider"},{"id":8897993,"accession":"0000950142-15-002621","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002621","line_url":"/filing/0000950142-15-002621#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":27.5,"price_display":"27.50","price_state":"stated","total_value":5500.0,"total_display":"5,500.00","total_whole":"5,500","shares_owned_after":3796362.0,"shares_owned_after_display":"3,796,362","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-11","filed_date":"2015-12-15","scope":"insider"},{"id":8897991,"accession":"0000950142-15-002576","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002576","line_url":"/filing/0000950142-15-002576#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"T2 Biosystems, Inc.","issuer_ticker":"TTOO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL III LP; Aisling Capital Partners III LP; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J","owner_display_name":"AISLING CAPITAL III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":307692.0,"shares_display":"307,692","price_per_share":9.75,"price_display":"9.75","price_state":"stated","total_value":2999997.0,"total_display":"2,999,997.00","total_whole":"2,999,997","shares_owned_after":2830992.0,"shares_owned_after_display":"2,830,992","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-12-09","filed_date":"2015-12-09","scope":"insider"},{"id":8707781,"accession":"0000950142-15-002461","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002461","line_url":"/filing/0000950142-15-002461#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; SCHIFF ANDREW N; Aisling Capital Partners III LP; ELMS STEVE","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":265000.0,"shares_display":"265,000","price_per_share":26.5,"price_display":"26.50","price_state":"stated","total_value":7022500.0,"total_display":"7,022,500.00","total_whole":"7,022,500","shares_owned_after":3796182.0,"shares_owned_after_display":"3,796,182","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-17","filed_date":"2015-11-19","scope":"insider"},{"id":8131979,"accession":"0000950142-15-002434","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-15-002434","line_url":"/filing/0000950142-15-002434#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1955.0,"shares_display":"1,955","price_per_share":27.4702,"price_display":"27.47","price_state":"stated","total_value":53704.241,"total_display":"53,704.24","total_whole":"53,704","shares_owned_after":3531182.0,"shares_owned_after_display":"3,531,182","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-13","filed_date":"2015-11-16","scope":"insider"},{"id":8131974,"accession":"0000950142-15-002434","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-002434","line_url":"/filing/0000950142-15-002434#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":76714.0,"shares_display":"76,714","price_per_share":27.6523,"price_display":"27.65","price_state":"stated","total_value":2121318.5422,"total_display":"2,121,318.54","total_whole":"2,121,319","shares_owned_after":3529207.0,"shares_owned_after_display":"3,529,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-12","filed_date":"2015-11-16","scope":"insider"},{"id":8897943,"accession":"0000950142-15-000894","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950142-15-000894","line_url":"/filing/0000950142-15-000894","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Esperion Therapeutics, Inc.","issuer_ticker":"ESPR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL PARTNERS LLC; AISLING CAPITAL PARTNERS, LP; ELMS STEVE; Aisling Capital II LP; SCHIFF ANDREW N; Purcell Dennis J","owner_display_name":"AISLING CAPITAL PARTNERS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67469.0,"shares_display":"67,469","price_per_share":106.26172909039707,"price_display":"106.26","price_state":"stated","total_value":7169372.6,"total_display":"7,169,372.60","total_whole":"7,169,373","shares_owned_after":1837125.0,"shares_owned_after_display":"1,837,125","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-04-24","filed_date":"2015-04-27","scope":"insider","n_lines":2},{"id":8897938,"accession":"0000950142-15-000894","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-000894","line_url":"/filing/0000950142-15-000894#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Esperion Therapeutics, Inc.","issuer_ticker":"ESPR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL PARTNERS LLC; AISLING CAPITAL PARTNERS, LP; ELMS STEVE; Aisling Capital II LP; SCHIFF ANDREW N; Purcell Dennis J","owner_display_name":"AISLING CAPITAL PARTNERS LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":109.1,"price_display":"109.10","price_state":"stated","total_value":16365000.0,"total_display":"16,365,000.00","total_whole":"16,365,000","shares_owned_after":1904594.0,"shares_owned_after_display":"1,904,594","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-04-23","filed_date":"2015-04-27","scope":"insider"},{"id":8779181,"accession":"0000950142-15-000194","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-000194","line_url":"/filing/0000950142-15-000194#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Versartis, Inc.","issuer_ticker":"VSAR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":145000.0,"shares_display":"145,000","price_per_share":17.25,"price_display":"17.25","price_state":"stated","total_value":2501250.0,"total_display":"2,501,250.00","total_whole":"2,501,250","shares_owned_after":2139568.0,"shares_owned_after_display":"2,139,568","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-27","filed_date":"2015-01-29","scope":"insider"},{"id":8354994,"accession":"0000950142-15-000157","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-15-000157","line_url":"/filing/0000950142-15-000157#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"AGILE THERAPEUTICS INC","issuer_ticker":"AGRX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":811966.0,"shares_display":"811,966","price_per_share":5.85,"price_display":"5.85","price_state":"stated","total_value":4750001.1,"total_display":"4,750,001.10","total_whole":"4,750,001","shares_owned_after":2983797.0,"shares_owned_after_display":"2,983,797","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-01-23","filed_date":"2015-01-27","scope":"insider"},{"id":6276981,"accession":"0001104659-14-061090","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-14-061090","line_url":"/filing/0001104659-14-061090#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"T2 Biosystems, Inc.","issuer_ticker":"TTOO","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N; Purcell Dennis J; AISLING CAPITAL III LP; Aisling Capital Partners III LLC","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":2523300.0,"shares_owned_after_display":"2,523,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-12","filed_date":"2014-08-14","scope":"insider"},{"id":6487140,"accession":"0001140361-14-031042","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-031042","line_url":"/filing/0001140361-14-031042#line-2","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":413077.0,"shares_display":"413,077","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":5370001.0,"total_display":"5,370,001.00","total_whole":"5,370,001","shares_owned_after":3452493.0,"shares_owned_after_display":"3,452,493","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-08-06","filed_date":"2014-08-06","scope":"insider"},{"id":6487134,"accession":"0001140361-14-031039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-031039","line_url":"/filing/0001140361-14-031039#line-2","is_derivative":false,"issuer_cik":"0001120478","issuer_name":"Loxo Oncology, Inc.","issuer_ticker":"LOXO","issuer_name_source":null,"issuer_url":"/issuer/0001120478","owner_cik":null,"owner_name":"Aisling Capital Partners III LLC; Purcell Dennis J; SCHIFF ANDREW N; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; GOLDSTEIN DOV A MD","owner_display_name":"Aisling Capital Partners III LLC","owner_url":null,"role":"Director, Officer (CFO and Treasurer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":"CFO and Treasurer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":413077.0,"shares_display":"413,077","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":5370001.0,"total_display":"5,370,001.00","total_whole":"5,370,001","shares_owned_after":3452493.0,"shares_owned_after_display":"3,452,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-06","filed_date":"2014-08-06","scope":"insider"},{"id":6990228,"accession":"0000950142-14-000941","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-14-000941","line_url":"/filing/0000950142-14-000941#line-1","is_derivative":false,"issuer_cik":"0000876378","issuer_name":"TRANSENTERIX INC.","issuer_ticker":"TRXC","issuer_name_source":null,"issuer_url":"/issuer/0000876378","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1037767.0,"shares_display":"1,037,767","price_per_share":4.0,"price_display":"4.00","price_state":"stated","total_value":4151068.0,"total_display":"4,151,068.00","total_whole":"4,151,068","shares_owned_after":8335819.0,"shares_owned_after_display":"8,335,819","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-04-21","filed_date":"2014-04-23","scope":"insider"},{"id":6294099,"accession":"0001209191-14-023549","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-14-023549","line_url":"/filing/0001209191-14-023549#line-6","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Versartis, Inc.","issuer_ticker":"VSAR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; SCHIFF ANDREW N; ELMS STEVE; AISLING CAPITAL III LP; Aisling Capital Partners III LP","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":1260000.0,"total_display":"1,260,000.00","total_whole":"1,260,000","shares_owned_after":1994568.0,"shares_owned_after_display":"1,994,568","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-26","filed_date":"2014-03-27","scope":"insider"},{"id":7090754,"accession":"0000950142-14-000705","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-14-000705","line_url":"/filing/0000950142-14-000705#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2649.0,"shares_display":"2,649","price_per_share":15.5738,"price_display":"15.57","price_state":"stated","total_value":41254.9962,"total_display":"41,255.00","total_whole":"41,255","shares_owned_after":3030175.0,"shares_owned_after_display":"3,030,175","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-21","filed_date":"2014-03-21","scope":"insider"},{"id":7090752,"accession":"0000950142-14-000705","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-14-000705","line_url":"/filing/0000950142-14-000705#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Aisling Capital Partners III LLC; Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":98000.0,"shares_display":"98,000","price_per_share":15.7407,"price_display":"15.74","price_state":"stated","total_value":1542588.6,"total_display":"1,542,588.60","total_whole":"1,542,589","shares_owned_after":3032824.0,"shares_owned_after_display":"3,032,824","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-20","filed_date":"2014-03-21","scope":"insider"},{"id":4769153,"accession":"0000950142-13-002267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-13-002267","line_url":"/filing/0000950142-13-002267#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Zeltiq Aesthetics Inc","issuer_ticker":"ZLTQ","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"SCHIFF ANDREW N; Purcell Dennis J; Aisling Capital Partners III LLC; ELMS STEVE; Aisling Capital Partners III LP; AISLING CAPITAL III LP","owner_display_name":"SCHIFF ANDREW N","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":575000.0,"shares_display":"575,000","price_per_share":12.22,"price_display":"12.22","price_state":"stated","total_value":7026500.0,"total_display":"7,026,500.00","total_whole":"7,026,500","shares_owned_after":3597742.0,"shares_owned_after_display":"3,597,742","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-11-14","filed_date":"2013-11-15","scope":"insider"},{"id":4769147,"accession":"0000950142-13-002123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-13-002123","line_url":"/filing/0000950142-13-002123#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"ADMA BIOLOGICS, INC.","issuer_ticker":"ADMA","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL PARTNERS, LP; ELMS STEVE; Purcell Dennis J; AISLING CAPITAL PARTNERS LLC; Aisling Capital II LP; SCHIFF ANDREW N","owner_display_name":"AISLING CAPITAL PARTNERS, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":411765.0,"shares_display":"411,765","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":3500002.5,"total_display":"3,500,002.50","total_whole":"3,500,003","shares_owned_after":3620143.0,"shares_owned_after_display":"3,620,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-10-22","filed_date":"2013-10-23","scope":"insider"},{"id":4228269,"accession":"0001179110-13-011142","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-13-011142","line_url":"/filing/0001179110-13-011142#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Esperion Therapeutics, Inc.","issuer_ticker":"ESPR","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"AISLING CAPITAL PARTNERS, LP; Purcell Dennis J; ELMS STEVE; AISLING CAPITAL PARTNERS LLC; SCHIFF ANDREW N; Aisling Capital II LP","owner_display_name":"AISLING CAPITAL PARTNERS, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":238119.0,"shares_display":"238,119","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":3333666.0,"total_display":"3,333,666.00","total_whole":"3,333,666","shares_owned_after":2054594.0,"shares_owned_after_display":"2,054,594","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-07-01","filed_date":"2013-07-01","scope":"insider"},{"id":5528461,"accession":"0001181431-13-029562","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-13-029562","line_url":"/filing/0001181431-13-029562#line-6","is_derivative":false,"issuer_cik":"0001131543","issuer_name":"AMBIT BIOSCIENCES CORP","issuer_ticker":"AMBI","issuer_name_source":null,"issuer_url":"/issuer/0001131543","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":423635.0,"shares_display":"423,635","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":3389080.0,"total_display":"3,389,080.00","total_whole":"3,389,080","shares_owned_after":1546444.0,"shares_owned_after_display":"1,546,444","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-05-21","filed_date":"2013-05-21","scope":"insider"},{"id":3160313,"accession":"0000950142-12-001608","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950142-12-001608","line_url":"/filing/0000950142-12-001608#line-2","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Durata Therapeutics, Inc.","issuer_ticker":"DRTX","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Aisling Capital Partners III LP; ELMS STEVE; Purcell Dennis J; SCHIFF ANDREW N; Aisling Capital Partners III LLC; AISLING CAPITAL III LP","owner_display_name":"Aisling Capital Partners III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1111111.0,"shares_display":"1,111,111","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":9999999.0,"total_display":"9,999,999.00","total_whole":"9,999,999","shares_owned_after":3130824.0,"shares_owned_after_display":"3,130,824","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-07-24","filed_date":"2012-07-25","scope":"insider"},{"id":2720481,"accession":"0000950142-12-000248","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-12-000248","line_url":"/filing/0000950142-12-000248#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"CEMPRA, INC.","issuer_ticker":"CEMP","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; AISLING CAPITAL PARTNERS, LP; Aisling Capital II LP; SCHIFF ANDREW N; AISLING CAPITAL PARTNERS LLC; ELMS STEVE","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1213663.0,"shares_display":"1,213,663","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":7281978.0,"total_display":"7,281,978.00","total_whole":"7,281,978","shares_owned_after":3293060.0,"shares_owned_after_display":"3,293,060","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-02-07","filed_date":"2012-02-09","scope":"insider"},{"id":8986164,"accession":"0001181431-11-053467","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-11-053467","line_url":"/filing/0001181431-11-053467#line-1","is_derivative":false,"issuer_cik":"0001172252","issuer_name":"Zeltiq Aesthetics Inc","issuer_ticker":"ZLTQ","issuer_name_source":null,"issuer_url":"/issuer/0001172252","owner_cik":null,"owner_name":"Purcell Dennis J; Aisling Capital Partners III LLC; AISLING CAPITAL III LP; Aisling Capital Partners III LP; ELMS STEVE; SCHIFF ANDREW N","owner_display_name":"Purcell Dennis J","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":769231.0,"shares_display":"769,231","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":10000003.0,"total_display":"10,000,003.00","total_whole":"10,000,003","shares_owned_after":4172742.0,"shares_owned_after_display":"4,172,742","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-10-24","filed_date":"2011-10-25","scope":"insider"},{"id":7745155,"accession":"0000950142-10-000415","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950142-10-000415","line_url":"/filing/0000950142-10-000415#line-1","is_derivative":false,"issuer_cik":"0001250195","issuer_name":"MAP Pharmaceuticals, Inc.","issuer_ticker":"MAPP","issuer_name_source":null,"issuer_url":"/issuer/0001250195","owner_cik":"0001250195","owner_name":"ELMS STEVE","owner_display_name":"ELMS STEVE","owner_url":"/insider/0001250195","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2090.0,"shares_display":"2,090","price_per_share":16.15,"price_display":"16.15","price_state":"stated","total_value":33753.5,"total_display":"33,753.50","total_whole":"33,754","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-10","filed_date":"2010-03-12","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":15,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":6,"open_market":true},{"code":"S","label":"Open-market sale","n":9,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":15},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001368514","name":"ADMA BIOLOGICS, INC.","url":"/issuer/0001368514","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2013-10-23","last_seen":"2026-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001094038","name":"Marker Therapeutics, Inc.","url":"/issuer/0001094038","role":"Director","n_filings":2,"first_seen":"2021-03-18","last_seen":"2024-12-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001783032","name":"Elevation Oncology, Inc.","url":"/issuer/0001783032","role":"Director, Other","n_filings":1,"first_seen":"2021-07-01","last_seen":"2021-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001061027","name":"SUNESIS PHARMACEUTICALS INC","url":"/issuer/0001061027","role":"Ten percent owner","n_filings":1,"first_seen":"2019-07-15","last_seen":"2019-07-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001581720","name":"Loxo Oncology, Inc.","url":"/issuer/0001581720","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2014-08-06","last_seen":"2018-07-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":1,"first_seen":"2016-07-06","last_seen":"2016-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001492674","name":"T2 Biosystems, Inc.","url":"/issuer/0001492674","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2014-08-14","last_seen":"2015-12-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001434868","name":"Esperion Therapeutics, Inc.","url":"/issuer/0001434868","role":"Ten percent owner","n_filings":2,"first_seen":"2013-07-01","last_seen":"2015-04-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001513818","name":"Versartis, Inc.","url":"/issuer/0001513818","role":"Ten percent owner","n_filings":2,"first_seen":"2014-03-27","last_seen":"2015-01-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001261249","name":"AGILE THERAPEUTICS INC","url":"/issuer/0001261249","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2015-01-27","last_seen":"2015-01-27"},{"type":"issuer","type_label":"ISSUER","cik":"0000876378","name":"TRANSENTERIX INC.","url":"/issuer/0000876378","role":"Ten percent owner","n_filings":1,"first_seen":"2014-04-23","last_seen":"2014-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001544116","name":"Durata Therapeutics, Inc.","url":"/issuer/0001544116","role":"Ten percent owner","n_filings":2,"first_seen":"2012-07-25","last_seen":"2014-03-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001415336","name":"Zeltiq Aesthetics Inc","url":"/issuer/0001415336","role":"Ten percent owner","n_filings":2,"first_seen":"2011-10-25","last_seen":"2013-11-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001131543","name":"AMBIT BIOSCIENCES CORP","url":"/issuer/0001131543","role":"Director","n_filings":1,"first_seen":"2013-05-21","last_seen":"2013-05-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001461993","name":"CEMPRA, INC.","url":"/issuer/0001461993","role":"Ten percent owner","n_filings":1,"first_seen":"2012-02-09","last_seen":"2012-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001401923","name":"MAP Pharmaceuticals, Inc.","url":"/issuer/0001401923","role":"Director","n_filings":1,"first_seen":"2010-03-12","last_seen":"2010-03-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001250195","retrieved_at":"2026-08-23T06:21:16+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}